Columnist Sam Kirton explores what options are available to help IPF patients meet the costs of their medical care and medications.

The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and only subcutaneously administered therapy for patients with epidermal growth ...

The US FDA approved 46 new drugs in 2025, despite a tumultuous year at the regulatory agency.

The US saw several new and expanded FDA indications this year. The top 5 most-read FDA approvals on AJMC.com included 4 novel therapies and 1 expanded indication, reflecting the growing number of ...

In 2025, respiratory news highlighted advances in lung imaging, expanded support for pulmonary rehabilitation and promising new and repurposed therapies for pulmonary fibrosis. Researchers used a data ...

The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults. Jascayd becomes the first and only preferential ...

Results from the FIBRONEER-ILD trial showed nerandomilast significantly slowed lung function decline in patients with PPF compared with placebo. The Food and Drug Administration (FDA) has expanded the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Healio Pulmonology has compiled the top news from the ...

Exciting news for those affected by progressive pulmonary fibrosis (PPF): The US FDA has granted approval for Jascayd (nerandomilast). This groundbreaking medication goes beyond merely alleviating ...

Following the clinical success of new agents like nerandomilast, the next critical steps for managing ILD involve dismantling financial and geographical barriers to access, and rigorously integrating ...